Loading...
•
Jun 30, 2023
Atai Q2 2023 Earnings Report
Atai reported Q2 2023 financial results and provided corporate updates.
Key Takeaways
Atai Life Sciences reported a net loss of $33.1 million for the three months ended June 30, 2023. The company's cash, cash equivalents, and short-term investments totaled $227.5 million as of June 30, 2023, expected to fund operations into 1H 2026.
Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with Schizophrenia
DMX-1002 (Ibogaine) Phase 1 results enable discussions with regulatory authorities to assess progressing into proof-of-concept study in patients with Opioid Use Disorder
Cash position and committed term loan funding is expected to fund operations into 1H 2026
Announced Phase 1 trial data of DMX-1002
Forward Guidance
The company expects its cash position and committed term loan funding will be sufficient to fund operations into 1H 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...